Better Quality of Life for People Living with Diabetes Through Validated Innovative Artificial Intelligence Applications
About Melissa
The MELISSA project aims to transform diabetes management for individuals with insulin-treated diabetes. By leveraging an Artificial Intelligence-based digital solution, MELISSA is designed to deliver personalized, efficient, and cost-effective care, adapting to each patient's unique needs, habits, and health progression. This approach promises to enhance the quality of life for millions by providing tailored support and improving clinical outcomes.
The necessity for MELISSA arises from the global surge in diabetes cases – 60 million people in Europe currently live with diabetes, and 36 million more are at high risk. By 2030, it is projected that over 10% of Europe’s population could be affected, posing severe consequences for individuals and the healthcare system alike. MELISSA’s AI-based solution could save 400,000 lives and reduce healthcare costs by €200 billion annually, marking a pivotal advancement in diabetes management.
Start Date1 June 2022
Duration4 Years
Budgetapprox. 8 Mil. €
12 Partners7 Countries
“Now is the time that we combine forces to relieve people with diabetes on insulin from the burden of managing daily blood glucose highs and lows.”
Bastiaan de Galan, MELISSA Coordinator
Universiteit Maastricht, The Netherlands
“A unique opportunity to offer a validated solution for personalized treatment to all patients who do not have the privilege to be equipped with a closed loop.”
Stephan Proennecke, Project Manager & Director
Industrialization at Debiotech S.A., Switzerland
“Transparent, trustworthy, validated, and unbiased AI tools have the potential to transform and revolutionise diabetes management.”
Prof. Dr Stavroula Mougiakakou, AI in Health and Nutrition Laboratory
ARTORG Center for Biomedical Engineering Research, University of Bern, Switzerland
News & Events
